Gubra Reports Q3 2026 Earnings and Pipeline Progress

Gubra reported Q3 2026 record-level earnings, supported by USD 50 million and EUR 10 million in partner milestone payments. CRO revenue grew 6%, with an EBIT margin of 25%. Two partnered obesity programs advanced to Phase 2, while GUB-UCN2 entered Phase 1/2a clinical testing. Gubra narrowed its 2026 CRO guidance to 2–6% growth and a 10–13% margin, and lowered its biotech cost guidance.